CG Oncology FY2029 EPS Forecast Increased by HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – HC Wainwright upped their FY2029 earnings estimates for CG Oncology in a research note issued to investors on Tuesday, April 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $3.12 per share for the year, up from their previous forecast of $2.79. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s FY2030 earnings at $6.06 EPS.

A number of other equities analysts have also recently issued reports on CGON. The Goldman Sachs Group restated a “buy” rating and set a $82.00 target price on shares of CG Oncology in a report on Monday, January 12th. Wedbush began coverage on CG Oncology in a research note on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target for the company. Truist Financial increased their price target on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Royal Bank Of Canada boosted their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CG Oncology has an average rating of “Moderate Buy” and a consensus target price of $70.67.

CG Oncology Stock Up 3.3%

Shares of CG Oncology stock opened at $69.81 on Wednesday. The business has a fifty day simple moving average of $59.73 and a 200 day simple moving average of $48.88. The stock has a market cap of $5.89 billion, a PE ratio of -33.72 and a beta of 0.70. CG Oncology has a 12 month low of $14.80 and a 12 month high of $69.90.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in shares of CG Oncology during the 4th quarter worth approximately $62,909,000. T. Rowe Price Investment Management Inc. bought a new stake in CG Oncology during the fourth quarter worth $17,547,000. Invesco Ltd. lifted its stake in CG Oncology by 10.9% in the fourth quarter. Invesco Ltd. now owns 38,140 shares of the company’s stock valued at $1,584,000 after acquiring an additional 3,761 shares during the last quarter. ADAR1 Capital Management LLC grew its position in shares of CG Oncology by 3.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 258,139 shares of the company’s stock valued at $10,718,000 after acquiring an additional 9,222 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of CG Oncology in the 4th quarter valued at about $1,400,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 11,145 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.40% of the stock is currently owned by corporate insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.